Frontiers | Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord
In recent years, gene therapy has been raising hopes toward viable treatment strategies for rare genetic diseases for which there has been almost exclusively supportive treatment. We here review this progress at the pre-clinical and clinical trial levels as well as market approvals within diseases that specifically affect the brain and spinal cord, including degenerative, developmental, lysosomal storage, and metabolic disorders. The field reached an unprecedented milestone when Zolgensma® (onasemnogene abeparvovec) was approved by the FDA and EMA for in vivo adeno-associated virus-mediated gene replacement therapy for spinal muscular atrophy. Shortly after EMA approved Libmeldy®, an ex vivo gene therapy with lentivirus vector-transduced autologous CD34-positive stem cells, for treatment of metachromatic leukodystrophy. These successes could be the first of many more new gene therapies in development that mostly target loss-of-function mutation diseases with gene replacement (e.g., Batten disease, mucopolysaccharidoses, gangliosidoses) or, less frequently, gain-of-toxic-function mutation diseases by gene therapeutic silencing of pathologic genes (e.g., amyotrophic lateral sclerosis, Huntington's disease). In addition, the use of genome editing as a gene therapy is being explored for some diseases, but this has so far only reached clinical testing in the treatment of mucopolysaccharidoses. Based on the large number of planned, ongoing, and completed clinical trials for rare...
;import{g as i,s as o,r as s,e as a,a as u,h as l,b as c,i as h,t as f,c as d,d as p,f as m,j as g,k as y,l as b,K as v,_ as w,S as E,m as _,o as C,w as M,n as S,p as O,q as B,u as D,v as I,x as T,y as x,z as R,A as N,U as k,H as F,B as L,C as P,Y as U,D as j,E as q,F as z,G as $,I as V,J as H,L as W,M as G,N as K,O as Z,P as Y,Q as J,R as X,T as Q,V as AA,W as eA,X as tA,Z as rA,$ as nA,a0 as iA,a1 as oA,a2 as sA,a3 as aA,a4 as uA,a5 as lA,a6 as cA,a7 as hA,a8 as fA,a9 as dA,aa as pA,ab as mA,ac as gA,ad as yA,ae as bA,af as vA,ag as wA,ah as EA,ai as _A,aj as CA,ak as MA,al as SA,am as OA,an
Explore this link on the map →related reading
- Curative gene therapies for rare diseases - PMCncbi.nlm.nih.gov
- Gap Mapgap-map.org
- Frontiers | Challenges for Therapeutic Applications of Opsin-Based Optogenetic Tools in Humansfrontiersin.org
- Frontiers | The Age of Brain Organoids: Tailoring Cell Identity and Functionality for Normal Brain Development and Disease Modelingfrontiersin.org
- Frontiers | The Role of NK Cells and Innate Lymphoid Cells in Brain Cancerfrontiersin.org
- Frontiers | Inflammation: Bridging Age, Menopause and APOEε4 Genotype to Alzheimer’s Diseasefrontiersin.org
- Frontiers | Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Diseasefrontiersin.org
- Frontiers | The Intense World Theory – A Unifying Theory of the Neurobiology of Autismfrontiersin.org
- Frontiers | Signal Generation, Acquisition, and Processing in Brain Machine Interfaces: A Unified Reviewfrontiersin.org
- The Frontier in 2025renaissancephilanthropy.org
- Frontiers | Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental modelsfrontiersin.org
- Frontiers | Deep Learning Driven Drug Discovery: Tackling Severe Acute Respiratory Syndrome Coronavirus 2frontiersin.org